Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05732662 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 17, 2023 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
Trial Details
NCT Number NCT05732662
Lead Sponsor The First People's Hospital of Changzhou
Conditions
(from sponsor)		 Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Related terms Esophageal Squamous Cell Carcinoma, Recurrence
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov